JP2014525749A - 炎症性腸疾患の治療のための新規化合物 - Google Patents

炎症性腸疾患の治療のための新規化合物 Download PDF

Info

Publication number
JP2014525749A
JP2014525749A JP2014524381A JP2014524381A JP2014525749A JP 2014525749 A JP2014525749 A JP 2014525749A JP 2014524381 A JP2014524381 A JP 2014524381A JP 2014524381 A JP2014524381 A JP 2014524381A JP 2014525749 A JP2014525749 A JP 2014525749A
Authority
JP
Japan
Prior art keywords
mir
nucleic acid
sequence
acid molecule
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014524381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525749A5 (enrdf_load_stackoverflow
Inventor
アレクサンダー シュミット
カタリーナ フェルトマン
クリストフ チチョン
Original Assignee
ヴェストファーレン ヴィルヘルム−ウニヴェルジテート ミュンスター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェストファーレン ヴィルヘルム−ウニヴェルジテート ミュンスター filed Critical ヴェストファーレン ヴィルヘルム−ウニヴェルジテート ミュンスター
Publication of JP2014525749A publication Critical patent/JP2014525749A/ja
Publication of JP2014525749A5 publication Critical patent/JP2014525749A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2014524381A 2011-08-12 2012-08-09 炎症性腸疾患の治療のための新規化合物 Ceased JP2014525749A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11006650 2011-08-12
EP11006650.3 2011-08-12
EP11185604 2011-10-18
EP11185604.3 2011-10-18
PCT/EP2012/065568 WO2013023982A1 (en) 2011-08-12 2012-08-09 Novel compounds for the treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
JP2014525749A true JP2014525749A (ja) 2014-10-02
JP2014525749A5 JP2014525749A5 (enrdf_load_stackoverflow) 2015-08-20

Family

ID=46826440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014524381A Ceased JP2014525749A (ja) 2011-08-12 2012-08-09 炎症性腸疾患の治療のための新規化合物

Country Status (6)

Country Link
US (1) US20140199402A1 (enrdf_load_stackoverflow)
EP (1) EP2742137A1 (enrdf_load_stackoverflow)
JP (1) JP2014525749A (enrdf_load_stackoverflow)
AU (1) AU2012296977A1 (enrdf_load_stackoverflow)
CA (1) CA2840030A1 (enrdf_load_stackoverflow)
WO (1) WO2013023982A1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9683263B2 (en) * 2013-05-20 2017-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection and treatment of irritable bowel syndrome
US10144915B2 (en) 2013-10-23 2018-12-04 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Reprogramming fibroblasts into cardiomyocytes
WO2016208880A1 (ko) * 2015-06-26 2016-12-29 주식회사 파마리서치프로덕트 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물
KR102733066B1 (ko) * 2015-06-26 2024-11-21 주식회사 파마리서치 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물
AU2020273726A1 (en) * 2019-05-14 2021-12-02 Hadasit Medical Research Services & Development Ltd. Milk derived extracellular vesicles for use in treating inflammatory bowel disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120877A2 (en) * 2008-03-26 2009-10-01 The Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
WO2010034479A1 (en) * 2008-09-23 2010-04-01 Eth Zurich Protective e. coli strains for reducing the salmonella typhimurium pathogen load in the intestines
JP2011507534A (ja) * 2007-12-27 2011-03-10 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
ES2534301T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507534A (ja) * 2007-12-27 2011-03-10 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法
WO2009120877A2 (en) * 2008-03-26 2009-10-01 The Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
WO2010034479A1 (en) * 2008-09-23 2010-04-01 Eth Zurich Protective e. coli strains for reducing the salmonella typhimurium pathogen load in the intestines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5014009605; ＪＯＵＲＮＡＬ　ＯＦ　ＨＥＰＡＴＯＬＯＧＹ Ｖｏｌ．　５０，　Ｎｏ．　２, 2009, ｐｐ．　３５８-３６９ *
JPN5014009606; ＥＸＰＥＲＩＭＥＮＴＡＬ　ＨＥＭＡＴＯＬＯＧＹ Ｖｏｌ．　３７，　Ｎｏ．　２, 2009, ｐｐ．　２４５-２５５ *
JPN6016015860; Ｅｘｐｅｒｔ　Ｏｐｉｎ　Ｂｉｏｌ　Ｔｈｅｒ． Ｖｏｌ．　１１，　Ｎｏ．　８, 2011, ｐｐ．　９９１-９９５ *

Also Published As

Publication number Publication date
EP2742137A1 (en) 2014-06-18
US20140199402A1 (en) 2014-07-17
AU2012296977A1 (en) 2014-01-23
CA2840030A1 (en) 2013-02-21
WO2013023982A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
del Pozo‐Acebo et al. Eating microRNAs: pharmacological opportunities for cross‐kingdom regulation and implications in host gene and gut microbiota modulation
Yu et al. Fermentation results in quantitative changes in milk-derived exosomes and different effects on cell growth and survival
Casado-Bedmar et al. MicroRNA and gut microbiota: tiny but mighty—novel insights into their cross-talk in inflammatory bowel disease pathogenesis and therapeutics
AU2017202497B2 (en) Bacterium for use as a probiotic for nutritional and medical applications
AU2016361583B2 (en) Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
EP2344626B1 (en) Reduced colonization of microbes at the mucosa
Guzman et al. Diet, microbiome, and the intestinal epithelium: an essential triumvirate?
US20120093874A1 (en) Method for screening for diet providing production of milk having immunoregulatory action
Mizuno et al. Exopolysaccharides from Streptococcus thermophilus ST538 modulate the antiviral innate immune response in porcine intestinal epitheliocytes
EP2169057B1 (en) Double-stranded rna originating in lactic acid bacterium
CN102470152A (zh) 用于治疗内毒素血症的乳酸菌和双歧杆菌
JP2014525749A (ja) 炎症性腸疾患の治療のための新規化合物
Yagnik et al. Construction of a new shuttle vector for DNA delivery into mammalian cells using non-invasive Lactococcus lactis
Bailey et al. Identification and characterisation of an iron-responsive candidate probiotic
JP2021118687A (ja) 新規のビフィドバクテリウムビフィダム菌株及び菌株由来多糖体
US10849939B2 (en) Probiotic formulation
Ogita et al. Suppression of Th17 response by Streptococcus thermophilus ST28 through induction of IFN-γ
Taibi et al. Time‐and strain‐specific downregulation of intestinal EPAS1 via miR‐148a by Bifidobacterium bifidum
CN115243697A (zh) 包含细菌物种的组合物及其相关方法
KR101611833B1 (ko) 비만 및 비만으로 야기된 대사성 질환의 예방 또는 치료를 위한 락토바실루스 아시도필루스 cbt la1 균주 및 이를 포함하는 조성물
JP7627369B2 (ja) 糖吸収促進用組成物
JP2022507079A (ja) クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）誘導性腸炎症の治療のためのｍｉＲ－２７ａ－５ｐマイクロＲＮＡの使用
Khokhlova et al. Heterologous expression of secreted biologically active human interleukin-10 in Bifidobacterium breve
PL217128B1 (pl) Syntetyczne geny kodujące fragmenty peptydowe naturalnych białek mielinowych przeznaczone do wywoływania efektu tolerancji pokarmowej, fragmenty DNA zawierające te geny, sposób otrzymywania tych peptydów w układzie mikrobiologicznym (bakteryjnym) oraz ich zastosowanie medyczne
PL241568B1 (pl) Nowe szczepy Lactococcus lactis, kompozycje je obejmujące oraz ich zastosowanie w zapobieganiu i leczeniu nowotworu raka jelita

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160923

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161114

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20170327